thalidomide has been researched along with Cerebral Ischemia in 6 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sixty patients with advanced multiple myeloma received 2-6 monthly treatment courses combining hyperfractionated cyclophosphamide (300 mg/m2 i." | 6.71 | Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. ( Berdel, WE; Bisping, G; Dominé, N; Fenk, R; Heinecke, A; Hentrich, M; Innig, G; Kienast, J; Koch, OM; Kropff, MH; Lang, N; Mitterer, M; Ostermann, H; Straka, C; Südhoff, T, 2003) |
| "Apremilast (APR) is a selective inhibitor of phosphodiesterase-4 involved in various neurological diseases, including stroke." | 5.72 | Apremilast exerts protective effects on stroke outcomes and blood-brain barrier (BBB) dysfunction through regulating Rho-associated protein kinase 2 expression. ( Cheng, Z; Meng, X; Wang, M, 2022) |
| "Thalidomide has shown protective effects in different models of ischemia/reperfusion damage." | 5.42 | Anti-apoptotic, anti-oxidant, and anti-inflammatory effects of thalidomide on cerebral ischemia/reperfusion injury in rats. ( Farfán, DJ; Medrano, JÁN; Ortiz-Plata, A; Palencia, G; Sánchez, A; Sotelo, J; Trejo-Solís, C, 2015) |
| "Sixty patients with advanced multiple myeloma received 2-6 monthly treatment courses combining hyperfractionated cyclophosphamide (300 mg/m2 i." | 2.71 | Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. ( Berdel, WE; Bisping, G; Dominé, N; Fenk, R; Heinecke, A; Hentrich, M; Innig, G; Kienast, J; Koch, OM; Kropff, MH; Lang, N; Mitterer, M; Ostermann, H; Straka, C; Südhoff, T, 2003) |
| "Apremilast (APR) is a selective inhibitor of phosphodiesterase-4 involved in various neurological diseases, including stroke." | 1.72 | Apremilast exerts protective effects on stroke outcomes and blood-brain barrier (BBB) dysfunction through regulating Rho-associated protein kinase 2 expression. ( Cheng, Z; Meng, X; Wang, M, 2022) |
| "Pomalidomide (POM) is a clinically available immunomodulatory and anti-inflammatory agent." | 1.51 | Pomalidomide Reduces Ischemic Brain Injury in Rodents. ( Chang, CF; Chen, KY; Chen, YH; Chiang, YH; de Cabo, R; Greig, NH; Hoffer, BJ; Kang, SJ; Lai, JH; Navas-Enamorado, I; Scerba, MT; Tsai, YR; Tweedie, D; Wu, JC, 2019) |
| "Thalidomide treatment significantly decreased the infarct volume and neurological deficits of MCAO/R rats." | 1.48 | The Neuroprotective Effect of Thalidomide against Ischemia through the Cereblon-mediated Repression of AMPK Activity. ( Asahi, T; Fujiwara, M; Hayashi, H; Sawamura, N; Takagi, N; Yamada, H; Yamada, M, 2018) |
| "Thalidomide has shown protective effects in different models of ischemia/reperfusion damage." | 1.42 | Anti-apoptotic, anti-oxidant, and anti-inflammatory effects of thalidomide on cerebral ischemia/reperfusion injury in rats. ( Farfán, DJ; Medrano, JÁN; Ortiz-Plata, A; Palencia, G; Sánchez, A; Sotelo, J; Trejo-Solís, C, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, M | 1 |
| Meng, X | 1 |
| Cheng, Z | 1 |
| Mohammed, RA | 1 |
| El-Yamany, MF | 1 |
| Abdel-Rahman, AA | 1 |
| Nassar, NN | 1 |
| Al-Shorbagy, MY | 1 |
| Sawamura, N | 1 |
| Yamada, M | 1 |
| Fujiwara, M | 1 |
| Yamada, H | 1 |
| Hayashi, H | 1 |
| Takagi, N | 1 |
| Asahi, T | 1 |
| Tsai, YR | 1 |
| Tweedie, D | 1 |
| Navas-Enamorado, I | 1 |
| Scerba, MT | 1 |
| Chang, CF | 1 |
| Lai, JH | 1 |
| Wu, JC | 1 |
| Chen, YH | 1 |
| Kang, SJ | 1 |
| Hoffer, BJ | 1 |
| de Cabo, R | 1 |
| Greig, NH | 1 |
| Chiang, YH | 1 |
| Chen, KY | 1 |
| Palencia, G | 1 |
| Medrano, JÁN | 1 |
| Ortiz-Plata, A | 1 |
| Farfán, DJ | 1 |
| Sotelo, J | 1 |
| Sánchez, A | 1 |
| Trejo-Solís, C | 1 |
| Kropff, MH | 1 |
| Lang, N | 1 |
| Bisping, G | 1 |
| Dominé, N | 1 |
| Innig, G | 1 |
| Hentrich, M | 1 |
| Mitterer, M | 1 |
| Südhoff, T | 1 |
| Fenk, R | 1 |
| Straka, C | 1 |
| Heinecke, A | 1 |
| Koch, OM | 1 |
| Ostermann, H | 1 |
| Berdel, WE | 1 |
| Kienast, J | 1 |
1 trial available for thalidomide and Cerebral Ischemia
| Article | Year |
|---|---|
Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Ischem | 2003 |
5 other studies available for thalidomide and Cerebral Ischemia
| Article | Year |
|---|---|
Apremilast exerts protective effects on stroke outcomes and blood-brain barrier (BBB) dysfunction through regulating Rho-associated protein kinase 2 expression.
Topics: Animals; Blood-Brain Barrier; Brain Ischemia; Claudin-5; Cyclic Nucleotide Phosphodiesterases, Type | 2022 |
Role of pERK1/2-NFκB signaling in the neuroprotective effect of thalidomide against cerebral ischemia reperfusion injury in rats.
Topics: Animals; Anti-Inflammatory Agents; Brain Ischemia; Disease Models, Animal; Hippocampus; Male; Memory | 2021 |
The Neuroprotective Effect of Thalidomide against Ischemia through the Cereblon-mediated Repression of AMPK Activity.
Topics: AMP-Activated Protein Kinases; Animals; ATP-Dependent Proteases; Brain Ischemia; Cell Death; Cell Li | 2018 |
Pomalidomide Reduces Ischemic Brain Injury in Rodents.
Topics: Angiogenesis Inhibitors; Animals; Brain Ischemia; Male; Mice; Rats; Thalidomide | 2019 |
Anti-apoptotic, anti-oxidant, and anti-inflammatory effects of thalidomide on cerebral ischemia/reperfusion injury in rats.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Brain Ischemia; Disease Models, Animal; Inflammation; M | 2015 |